Early recognition of growth abnormalities permitting early intervention

Haymond, Morey W.; Kappelgaard, Anne-Marie; Czernichow, P; Biller, Beverly M. K.; Takano, Koji; Kieß, Wieland

doi:10.1111/apa.12266

Cited by 72 publications

(74 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Growth failure and short stature in childhood are often early symptoms of an underlying disorder requiring appropriate diagnosis and management to achieve individual growth potential [1, 2]. Human recombinant growth hormone (GH) therapy is an approved treatment for a number of growth-related conditions, most commonly GH deficiency (GHD).…”

Section: Introductionmentioning

confidence: 99%

Growth Hormone Treatment for Short Stature in the USA, Germany and France: 15 Years of Surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS)

et al. 2018

View full text Add to dashboard Cite

Background/Aims: To describe characteristics, auxological outcomes and safety in paediatric patients with growth disorders treated with growth hormone (GH), for cohorts from the USA, Germany and France enrolled in GeNeSIS, a post-authorisation surveillance programme. Methods: Diagnosis and biochemical measurement data were based on reporting from, and GH treatment was initiated at the discretion of, treating physicians. Auxological outcomes during the first 4 years of GH treatment and at near-adult height (NAH) were analysed. Serious and treatment-emergent adverse events were described. Results: Children in the USA (n = 9,810), Germany (n = 2,682) and France (n = 1,667) received GH (dose varied between countries), most commonly for GH deficiency. Across diagnostic groups and countries, mean height velocity standard deviation score (SDS) was > 0 and height SDS increased from baseline during the first 4 years of treatment, with greatest improvements during year 1. Most children achieved NAH within the normal range (height SDS >−2). No new or unexpected safety concerns were noted. Conclusion: GH treatment improved growth indices to a similar extent for patients in all three countries despite variations in GH doses. Data from these three countries, which together contributed > 60% of patients to GeNeSIS, indicated no new safety signals and the benefit-risk profile of GH remains unchanged.

show abstract

Section: Introductionmentioning

confidence: 99%

Growth Hormone Treatment for Short Stature in the USA, Germany and France: 15 Years of Surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…4 Further evaluation of pathological short stature is done as per various etiologies. 5,6 Familial short stature and Constitutional Growth delay are considered as normal variants. 7 While the pathological short stature includes a wide variety of underlying disorders.…”

Section: Introductionmentioning

confidence: 99%

An aetiological evaluation of short stature

Phirke

Khot

2017

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Short stature can be a normal variant or secondary to an underlying disorder. It is necessary to evaluate short stature to differentiate a normal from pathological short stature and thus decide the further treatment needed. This study was conducted at a tertiary care hospital to find out the various etiologies of short statureMethods: An observational study was conducted on 49 children in age of 2-12 years with short stature. They were grouped as normal variants and pathological short stature depending on upper-lower segment ratio the study group was later divided into proportionate and disproportionate short stature. They were further investigated to find out the etiology of the short stature. The bone age of all groups was compared with the chronological age to calculate the bone age retardation.Results: Out of 49 children 26.5% were normal variants and 73.4% as pathological type. 77.7% of pathological short stature were proportionate type. The male:female ratio was 1:1.4. Chronic systemic disorders were detected in 24.48% while malnutrition and endocrine disorders constituted 12% each. The bone age retardation in endocrine disorders was 0.47.Conclusions: Chronic systemic disorders were commonest cause of pathological short stature in this study. Females were predominantly affected in all groups and bone age retardation was maximum in endocrine disorders, thus indicating that early diagnosis and management of these disorders is necessary to decrease the growth retardation in these children. An understanding of short stature not only permits to differentiate a normal variant from an underlying disorder but also helps in modifying the course by means of early intervention.

show abstract

“…The WHO has also developed growth monitoring charts; and a training course is available to help in assessing child growth [39]. Haymond et al suggested that, for a good differential diagnosis, it is essential to get medical history, family history, physical examination, analysis of the growth curve, and weight-for-height measurements [40]. A review by Nwosu and Lee on evaluation of short and tall stature in children suggested that firstly a thorough history and physical examination should be conducted and the laboratory investigations should then be based on the finding of these examinations [1].…”

Section: Resultsmentioning

confidence: 99%

Challenges in the Diagnosis and Management of Growth Hormone Deficiency in India

John¹,

Koledova

Kumar

et al. 2016

International Journal of Endocrinology

View full text Add to dashboard Cite

In clinical practice, every year approximately 150,000 children are referred with short stature (SS) based on a cut-off of fifth percentile. The most important endocrine and treatable cause of SS is growth hormone deficiency (GHD). The lack of reliable data on the prevalence of GHD in India limits estimation of the magnitude of this problem. The diagnosis and treatment of GHD are hurdled with various challenges, restricting the availability of growth hormone (GH) therapy to only a very limited segment of the children in India. This review will firstly summarize the gaps and challenges in diagnosis and treatment of GHD based on literature analysis. Subsequently, it presents suggestions from the members at advisory board meetings to overcome these challenges. The advisory board suggested that early initiation of the therapy could better the chances of achieving final adult height within the normal range for the population. Education and awareness about growth disorders among parents, regular training for physicians, and more emphasis on using the Indian growth charts for growth monitoring would help improve the diagnosis and treatment of children with GHD. Availability of an easy-to-use therapy delivery system could also be beneficial in improving adherence and achieving satisfactory outcomes.

show abstract

Early recognition of growth abnormalities permitting early intervention

Cited by 72 publications

References 48 publications

Growth Hormone Treatment for Short Stature in the USA, Germany and France: 15 Years of Surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS)

Growth Hormone Treatment for Short Stature in the USA, Germany and France: 15 Years of Surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS)

An aetiological evaluation of short stature

Challenges in the Diagnosis and Management of Growth Hormone Deficiency in India

Contact Info

Product

Resources

About